Updated safety data from the EORTC 1333/PEACE-3 trial show a marked reduction in the risk for fractures with the use of bone protecting agents in men with metastatic castration-resistant prostate cancer and bone metastases.

The number and location of bone metastases, as determined by conventional imaging, are associated with the survival benefit of prostate radiotherapy in men with newly diagnosed metastatic prostate cancer, STAMPEDE trial data show.

Treatment with the multikinase inhibitor cabozantinib is associated with better outcomes than everolimus therapy in patients with previously treated advanced renal cell carcinoma and bone involvement, suggests a prespecified subgroup analysis of the phase III METEOR trial.

The ARTO trial included 157 patients who had not received prior systemic treatment for metastatic CRPC and had no more than three bone or nodal metastatic lesions (patients with visceral lesions were excluded).

Older individuals with a history of cancer, especially those with a more recent diagnosis, have a higher risk for frailty-related bone fractures than their cancer-free counterparts, suggests a large longitudinal study.

Moreover, an OS benefit with the combination treatment was noted among subgroups of patients with special characteristics, including those with sarcomatoid features, history of nephrectomy, and liver, bone, or lung metastases at baseline.

The addition of bone resorption inhibitors to abiraterone acetate plus prednisone is associated with improved survival outcomes in patients with metastatic castration-resistant prostate cancer and bone metastases, especially if they have high-volume disease, researchers report.

The risk for osteonecrosis of the jaw following zoledronic acid treatment in patients with bone metastases is associated with cancer type, oral health, and dosing frequency, US researchers report.

The most frequent serious TRAEs at grade 3 or worse were platelet count decreases (9 vs 2%) and bone marrow toxicity (4 vs <1%).

For the majority (89.9%) of patients, the metastases were in a single organ, most commonly the lung (44.6%), bone (29.8%), or liver (13.3%).

Men with metastatic castration-resistant prostate cancer who receive ipilimumab after radiotherapy to bone metastases have a significantly better long-term survival rate than those who receive placebo, study findings indicate.

New metastases occurred in 30.7% of the 1139 patients with evaluable data.

The addition of CDK4/6 inhibitors was associated with a significant OS gain regardless of whether participants were premenopausal (HR=1.32) or postmenopausal (HR=1.34), had visceral (HR=1.31) or bone-only (HR=1.22) metastases, were aged at least 65 years (HR=1.38) or were younger (HR=1.25), or received treatment in the first- (HR=1.35) or second-line (HR=1.30).

The efficacy benefits afforded by nivolumab–cabozantinib were consistently maintained across predefined subgroups, including those defined by IMDC risk status, tumor PD-L1 expression, and bone metastases, commented Choueiri.

The patient was admitted to the hospital for fever and symptomatic bone metastases pain that was unresponsive to ceftriaxone administered in the outpatient setting.

Matthew Sydes (MRC Clinical Trials Unit at UCL, London, UK) and co-researchers report in The Lancet that the data remain immature for the trial’s primary endpoint of freedom from distant metastases and overall survival.

The study, published in The Lancet Oncology, comprised three cohorts that included metastatic urothelial cancer patients with measurable disease as per RECIST criteria (n=49) or bone-only metastases (n=6), as well as patients with rare genitourinary tract tumors (n=13).